Precision Biosciences Inc.
A clinical-stage gene editing company whose ARCUS platform, built on a naturally occurring enzyme first found in green algae, develops therapies for chronic hepatitis B and Duchenne muscular dystrophy. Three Duke University postdocs founded the company in 2006 after their lab discovery placed second in a university start-up challenge, and the earliest ARCUS work actually edited crops like corn and soybean before turning to human medicines.
Granted 192.6K · Sold 58.8K
Granted 45.8K · Sold 15.1K
Granted 75.6K · Sold 24.7K
Granted 43.8K · Sold 14.4K
Granted 21.0K
Granted 21.0K · Bought 3.0K
Granted 21.0K · Bought 2.8K
Granted 21.0K · Bought 5.4K
Granted 21.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Amoroso MichaelPresident and CEO, Director · 8 transactions | +122.2% | 243.4K | 192.6K | — | 58.8K |
| Smith J. JeffersonChief Research Officer · 6 transactions | +35.6% | 129.9K | 45.8K | — | 15.1K |
| Kelly John AlexanderChief Financial Officer · 8 transactions | +71.3% | 125.9K | 75.6K | — | 24.7K |
| Scimeca DarioGeneral Counsel and Secretary · 8 transactions | +125.8% | 56.5K | 43.8K | — | 14.4K |
| Buehler KevinDirector · 1 transaction | +74.6% | 49.1K | 21.0K | — | — |
| Germano Geno JDirector · 2 transactions | +114.9% | 44.9K | 21.0K | 3.0K | — |
| Brown MelindaDirector · 3 transactions | +115.6% | 44.3K | 21.0K | 2.8K | — |
| Frankel StanleyDirector · 3 transactions | +187.5% | 40.5K | 21.0K | 5.4K | — |
| Pire Shari LisaDirector · 1 transaction | +149.7% | 35.0K | 21.0K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -101.8K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.